Author: BusinessWire

First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is schedul…

WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #bondoffering–Charles River Laboratories International, Inc. (NYSE: CRL) announced that on March 8, 2021 it priced its private offering (the “offering”) of $500 million in aggregate principal amount of 3.750% s…

To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative…

Collaboration designed to uncover new drug-target interactions at genome scale
BOSTON & GHENT, Belgium & HOUSTON–(BUSINESS WIRE)–Orionis Biosciences, a life sciences company pioneering innovation in genome-scale drug discovery, and The University of…

Melior’s therapeutic candidate, tolimidone, is:

Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications

A repositioned drug that has been demonstrated to be safe and well-tolerated in previous c…

Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated

Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores …

Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated

Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores …

To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative…

WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #bondoffering–Charles River Laboratories International, Inc. (NYSE: CRL) announced that on March 8, 2021 it priced its private offering (the “offering”) of $500 million in aggregate principal amount of 3.750% s…